Title: Quantification of microRNA-181b in Egyptian Acute Myeloid Leukemia Patients and its Relation to Prognosis
Authors: Iman M Omar, Dina A Fouad, Deena M M Habashy, Doaa G Eissa, Mariam F Abdel-Maksoud
DOI: http://dx.doi.org/10.18535/jmscr/v4i3.46
Unique micro RNA (miRNA) expression signatures are aberrantly expressed in acute myeloid leukemia (AML). Certain miRNA signatures have been associated with prognosis of AML, one of these is miR-181b. We aimed to quantify miR-181b in AML Egyptian adult patients and evaluate its prognostic significance in those patients. Eighty newly diagnosed AML patients with 40 age and sex matching healthy volunteers as a control group were studied for the expression of miR-181b by stem-loop quantitative reverse-transcription polymerase chain reaction (qRT- PCR).miR-181b expression level was higher in patients’ group than controls (p=0.013). Patients with miR-181b ³ 6.0 were associated with favorable molecular abnormalities and most of them achieved complete remission (CR), whereas most of patients with miR-181b< 6.0 were associated with unfavorable ones and failed to achieve CR. Patients with miR- 181b values ≥ 6 showed significantly higher mean survival than patients with values <6 (35±0.7, 14.6±2 month respectively, p<0.001).Low value of miRNA181b was identified as an independent predictor of bad prognosis. High expression level of miR-181b is detected in Egyptian AML adult patients identifying a distinct group with favorable prognosis Keywords: miR-181b, acute myeloid leukemia, prognosis 1. Zhi F, Cao X, Xie X, Wang B, Dong W, Gu W, et al. Identification of Circulating MicroRNAs as Potential Biomarkers for Detecting Acute Myeloid Leukemia. Plos One 2013; 8(2): e56718. 2. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009; 37: 98-104. 3. Chen H, Chen Q, Fang M, Mi Y. microRNA-181b targets MLK2 in HL-60 cells. SciChinaLife Sci 2010; 53(1): 101-6. 4. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc 2008; 3 (6): 1101-8. 5. Stewart CC. Clinical applications of flow cytometry. Immunologic methods for measuring cell membrane and cytoplasmic antigens. Cancer 1992; 69(6 suppl):1543–52. 6. Hayashi Y, Eguchi M, Sugita K, Nakazawa S, Sato T, Kojima S, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down’s syndrome. Blood 1988; 72 (1):15–23. 7. Swerdlow SH, Campo E, Harris NL, Jaffe, ES, Pileri SA, Stein H, et al,editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. 8. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet; 2010, Blood 115:453–474. 9. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J ClinOncol. 2003; 21(24):4642-9. 10. Fey MF, Buske C. Acute Myeloblastic Leukaemia in Adult Patients: ESMO Clinical Practice Guidelines. Ann Oncol 2013; 24 (Suppl 6): 138-43. 11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2) DDCT Method. Methods 2001; 25:402–8. 12. Rieu I, Powers SJ. Real-time quantitative RT-PCR: design, calculations, and statistics. Plant Cell 2009; 21:1031–3. 13. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al . Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53–9. 14. Mitelman F, editor. ISCN 1995. Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature.Karger S; Basel, 1995; p. 1-110. 15. Dixon-McIver A, East P, Mein CA, Cazier J, Molloy G,Chaplin T, et al. Distinctive patterns of MicroRNA expression associated with karyotype in acute myeloid leukaemia. PLoS ONE 2008; 3(5): e2141. 16. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117 (4):1121-9. 17. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proceedings of the National Academy of Sciences of the United States of America 2008; 105(40):15535-40. 18. Havelange V, Garzon R, Croce CM. MicroRNAs: new players in acute myeloid leukemia. Br J Cancer 2009; 101(5):743-8. 19. Hollink I, van den Heuvel-Eibrink MM, Arentsen-Peters S, Pratcorona M, Abbas S, Kuipers J, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011; 118 (13): 3645-56. 20. Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: Promising Biomarkers of Human Cancer. Asian Pacific J Cancer Prev 2011; 12 (5): 1117-25.Abstract
References